NASDAQ:VXRT

Vaxart Stock Insider Trading

Healthcare > Biotechnology

Buy VXRT

*Your capital is at risk

$0.600

-0.0049 (-0.81%)

At Close: Jun 03, 2026

Vaxart Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.66. In total, the insiders bought 23.07M and sold 408.43K VXRT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.66
● Buy	23.07M shares
● Sell	408.43K shares
81% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 24, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 94.66. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 02, 2026 Sell	Common Stock F-InKind	Tucker Sean SVP, Chief Scientific Officer	Officer	9 265 Value: $6K
Feb 02, 2026 Sell	Common Stock F-InKind	Berg Edward B SVP, General Counsel	Officer	9 265 Value: $6K
Feb 02, 2026 Sell	Common Stock F-InKind	Cummings James F. Chief Medical Officer	Officer	7 965 Value: $5K
Dec 04, 2025 Sell	Common Stock F-InKind	Lo Steven President, Chief Exec Officer	CEO / President	54 153 Value: $20.0K
Dec 04, 2025 Buy	Common Stock A-Award	Lo Steven President, Chief Exec Officer	CEO / President	151 351 Value: $55.2K
Nov 17, 2025 Buy	Common Stock P-Purchase	Watson W. Mark Director	Director	15 000 Value: $6K
Nov 17, 2025 Buy	Common Stock P-Purchase	Watson W. Mark Director	Director	5 000 Value: $2K
Nov 17, 2025 Buy	Common Stock P-Purchase	Heron Elaine J Director	Director	23 217 Value: $9K
Nov 17, 2025 Buy	Common Stock P-Purchase	Heron Elaine J Director	Director	16 783 Value: $7K
Aug 15, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	50 000 Value: $18.5K
Aug 15, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	50 000 Value: $17.5K
Aug 15, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	50 000 Value: $17.5K
Aug 15, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	50 000 Value: $18.5K
Jul 30, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	25 874 Value: $10K
Jul 30, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	25 874 Value: $10K
Jul 29, 2025 Buy	Common Stock P-Purchase	Watson W. Mark Director	Director	10 000 Value: $4K
Jul 29, 2025 Buy	Common Stock P-Purchase	Watson W. Mark Director	Director	10 000 Value: $4K
Jul 28, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	20 000 Value: $8K
Jul 28, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	20 000 Value: $8K
Jul 25, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	20 000 Value: $8K
Jul 25, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	20 000 Value: $8K
Jul 17, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	794 Value: $302
Jul 17, 2025 Buy	Common Stock P-Purchase	Finney Kevin Director	Director	794 Value: $302
Jun 13, 2025 Buy	Common Stock A-Award	Finney Kevin Director	Director	6 103 Value: $4K
Jun 13, 2025 Buy	Stock Option (right to buy) A-Award	Finney Kevin Director	Director	36 392 Value: $25.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VAXART

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the t...

Read Full Profile Here